Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging. A feasibility study

Academic Radiology

Volumn 17, Issue 11, 2010, Pages 1326-1333

  Fenchel, Michael ^a   Konaktchieva, Marina ^a   Weisel, Katja ^a   Kraus, Sabina ^a   Claussen, Claus D ^a   Horger, Marius ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antiangiogenic therapy; Arterial spin labeling (ASL); Diffusion weighted imaging; Multiple myeloma; Tumor angiogenesis

Indexed keywords

BORTEZOMIB; LENALIDOMIDE;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTERIAL SPIN LABELING; ARTICLE; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIFFUSION WEIGHTED IMAGING; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDIES; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPIN LABELS; TREATMENT OUTCOME;

EID: 77957655689     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2010.08.002     Document Type: Article

References (20)

1. Hose D., Moreaux J., Meissner T., et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009, 114:128-143.
2. Sezer O., Jakob C., Eucker J., et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001, 66:83-88.
3. Kumar S., Fonseca R., Dispenzieri A., et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002, 119:665-671.
4. Hillengass J., Wasser K., Delorme S., et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 2007, 13:475-481.
5. Warmuth C., Gunther M., Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003, 228:523-532.
6. Shih T.T., Hou H.A., Liu C.Y., et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009, 113:3161-3167.
7. Tuncbilek N., Kaplan M., Altaner S., et al. Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer. Am J Roentgenol 2009, 192:949-955.
8. Parkes L.M., Rashid W., Chard D.T., et al. Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. Magn Reson Med 2004, 51:736-743.
9. Takeuchi M., Matsuzaki K., Nishitani H. Diffusion-weighted magnetic resonance imaging of endometrial cancer: differentiation from benign endometrial lesions and preoperative assessment of myometrial invasion. Acta Radiol 2009, 50:947-953.
10. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
11. Hillengass J., Zechmann C., Bäuerle T., et al. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res 2009, 15:3118-3125.
12. Rahmouni A., Montazel J.L., Divine M., et al. Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. Radiology 2003, 229:710-717.
13. Nosàs-Garcia S., Moehler T., Wasser K., et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. J Magn Reson Imaging 2005, 22:154-162.
14. Raab M.S., Podar K., Breitkreutz I., et al. Multiple myeloma. Lancet 2009, 374:324-339.
15. Baur A., Bartl R., Pellengahr C., et al. Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings. Cancer 2004, 101:2599-2604.
16. Kwee T.C., Quarles van Ufford H.M., Beek F.J., et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 2009, 44:683-690.
17. Silvera S., Oppenheim C., Touze E., et al. Spontaneous intracerebral hematoma on diffusion-weighted images: influence of T2-shine-through and T2-blackout effects. AJNR Am J Neuroradiol 2005, 26:236-241.
18. Noguchia T., Yoshiuraa T., Hiwatashia A., et al. Perfusion imaging of brain tumors using arterial spin-labeling: correlation with histopathologic vascular density. AJNR Am J Neuroradiol 2008, 29:688-693.
19. Durie B.G.M. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006, 42:1539-1543.
20. Dimopoulos M., Terpos E., Comenzo R.L., et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009, 23:1545-1556.